

ENDOSCOPIC INTRALUMINAL DEVICE FOR MORBID OBESITY AND DIABETES TREATMENT

Ref AP-HP 12-275

Photo Credits : AP-HP



Background

Morbid obesity reduces life expectancy by 10 to 15 years and is associated with comorbidities like cardio-vascular diseases, diabetes, high blood pressure and dyslipidemia. Surgical treatment is indicated for patients with BMI higher than 40, or higher than 35 with comorbidities. Yet surgical treatment results in a 1% mortality rate that can go up to 10% with the most efficient procedures. Alternatively, mini invasive trans-oral endoscopic devices (intra-gastric balloon and duodeno-jejunal bypass liner) are available but currently proposed as distinct treatments. Unfortunately, the use of endoscopic devices also results in complications: migration, perforation, GI occlusion. Moreover, the duodeno-jejunal bypass liner can move and cause damages to the stomach.

Technology

The technology is an endoscopic intraluminal device implanted temporarily. The structure of the device allows a double action by restricting the quantity ingested (intra gastric balloon effect) and also limiting bolus absorption (duodeno-jejunal bypass liner effect).

The double action results from the new innovative design of the device and reduces both the migration and twisting rates of the prosthesis.

The device implantation is suitable for ambulatory surgery, which reduces duration of hospitalization and health care costs for patients.

Type of partnership desired

AP-HP is looking for an industrial partner for the development of the technology and offers to grant license on the patent.

Keywords

Endoscopic – obesity – diabetes – treatment – mini invasive – device

Intellectual property

Patent family:

FR3013212 (A1)

WO2015071496 (A1)

Stage of development

Prototype in development

Contacts:

Julien Matricon, PhD

Office : 33 (0) 1 44 84 17 18

Benoît Labarthe, PharmD, PhD

Office : 33 (0) 1 44 84 17 74

Fax : 33 (0) 1 44 84 17 00

drc-licensing-ottpi@aphp.fr